Abstract
The activity of rokitamycin, a new macrolide with a 16-member ring, was tested against Borrelia burgdorferi in vitro. The antibiotic had a lower MIC at which 50% of the isolates are inhibited than erythromycin, the parent 14-member macrolide, but the same MIC at which 50% of the isolates are inhibited as the other recent 14- and 15-member macrolides, like clarithromycin and azithromycin. The MBC was equal to the MIC at which 50% of the isolates are inhibited, so rokitamycin can be considered bactericidal against B. burgdorferi. The sensitivity of the Borrelia strains tested was not correlated with the particular species Burgdorferi sensu stricto, B. garinii, and B. afzelii or with the number of subcultures of the isolates.
Full Text
The Full Text of this article is available as a PDF (148.7 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Baba S., Kinoshita H., Mori Y., Suzuki K., Shimada J., Kawamura S., Sugita R., Fujimaki Y., Sanbe B., Ogura S. [Studies of isolated organisms from otorhinolaryngological infections and their susceptibilities to macrolide antibiotics]. Jpn J Antibiot. 1985 May;38(5):1355–1367. [PubMed] [Google Scholar]
- Baranton G., Postic D., Saint Girons I., Boerlin P., Piffaretti J. C., Assous M., Grimont P. A. Delineation of Borrelia burgdorferi sensu stricto, Borrelia garinii sp. nov., and group VS461 associated with Lyme borreliosis. Int J Syst Bacteriol. 1992 Jul;42(3):378–383. doi: 10.1099/00207713-42-3-378. [DOI] [PubMed] [Google Scholar]
- Cinco M., De Giovannini R., Fattorini P., Florian F., Graziosi G. Classification of Italian isolates of Borrelia burgdorferi into three genomic groups. New Microbiol. 1993 Oct;16(4):323–332. [PubMed] [Google Scholar]
- Dever L. L., Jorgensen J. H., Barbour A. G. Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi. Antimicrob Agents Chemother. 1993 Aug;37(8):1704–1706. doi: 10.1128/aac.37.8.1704. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dever L. L., Jorgensen J. H., Barbour A. G. In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies. J Clin Microbiol. 1992 Oct;30(10):2692–2697. doi: 10.1128/jcm.30.10.2692-2697.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Johnson R. C., Kodner C., Russell M., Girard D. In-vitro and in-vivo susceptibility of Borrelia burgdorferi to azithromycin. J Antimicrob Chemother. 1990 Jan;25 (Suppl A):33–38. doi: 10.1093/jac/25.suppl_a.33. [DOI] [PubMed] [Google Scholar]
- Johnson R. C., Kodner C., Russell M. In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents. Antimicrob Agents Chemother. 1987 Feb;31(2):164–167. doi: 10.1128/aac.31.2.164. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kirst H. A., Sides G. D. New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy. Antimicrob Agents Chemother. 1989 Sep;33(9):1419–1422. doi: 10.1128/aac.33.9.1419. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Levin J. M., Nelson J. A., Segreti J., Harrison B., Benson C. A., Strle F. In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents. Antimicrob Agents Chemother. 1993 Jul;37(7):1444–1446. doi: 10.1128/aac.37.7.1444. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Preac-Mursic V., Wilske B., Schierz G., Süss E., Gross B. Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi. Eur J Clin Microbiol Infect Dis. 1989 Jul;8(7):651–653. doi: 10.1007/BF01968150. [DOI] [PubMed] [Google Scholar]
- Schentag J. J., Ballow C. H. Tissue-directed pharmacokinetics. Am J Med. 1991 Sep 12;91(3A):5S–11S. doi: 10.1016/0002-9343(91)90394-d. [DOI] [PubMed] [Google Scholar]